|
| | RUFLOXACIN Basic information |
| Product Name: | RUFLOXACIN | | Synonyms: | RUFLOXACIN;ISF-09334;AKOS NCG1-0068;8-FLUORO-9-(4-METHYL-PIPERAZIN-1-YL)-6-OXO-2,3-DIHYDRO-6H-1-THIA-3A-AZA-PHENALENE-5-CARBOXYLIC ACID;9-Fluom-2，3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1，2，3-de]-1，4-benzothiazine-6-carboxylic acid;Mones;Qari;Tebraxin | | CAS: | 101363-10-4 | | MF: | C17H18FN3O3S | | MW: | 363.41 | | EINECS: | | | Product Categories: | ACTIVE PHARMACEUTICAL INGREDIENTS | | Mol File: | 101363-10-4.mol |  |
| | RUFLOXACIN Chemical Properties |
| Boiling point | 574.6±50.0 °C(Predicted) | | density | 1.54 | | storage temp. | 2-8°C | | pka | 5.21±0.20(Predicted) | | CAS DataBase Reference | 101363-10-4 |
| | RUFLOXACIN Usage And Synthesis |
| Definition | ChEBI: Rufloxacin is a member of quinolines, a quinolone antibiotic and a fluoroquinolone antibiotic. | | Pharmaceutical Applications | A tricyclic fluoroquinolone formulated as the hydrochloride salt. It is inactive against Gram-positive cocci with MICs >2 mg/L. It displays weak activity in vitro against Enterobacteriaceae with the MIC for most species >1 mg/L. Activity against Ps. aeruginosa is poor (MIC 16–32 mg/L). After loading doses of 400 and 600 mg followed with 9 days of either 200 or 300 mg, mean peak plasma levels were around 4.5–7 mg/L, respectively. The mean apparent elimination halflife was 44 h. Approximately 50% is eliminated in the urine.
It has been used in urinary tract infection and chronic prostatitis, but clinical experience is limited. |
| | RUFLOXACIN Preparation Products And Raw materials |
|
